The Sunday Read: ‘Ozempic Could Crush the Junk Food Industry. But It Is Fighting Back.’

The podcast dives into the transformative effects of GLP-1 agonists, such as Ozempic, Wagovi, and Moundjaro, noting their ability to significantly reduce appetite by mimicking the hormone that signals fullness to the brain. As a result, users are not only eating less but are also changing their food preferences, shifting toward healthier, unprocessed options like fresh fruits and vegetables instead of traditional, processed snacks. One case study focused on a 52-year-old man who, under the influence of Ozempic, has drastically altered his shopping habits and food preferences, abandoning sugary snacks for healthier alternatives.

With around 40% of Americans classified as obese and the potential for 24 million people to be using GLP-1 drugs by 2035, the podcast highlights the looming threat these drugs pose to the over $1 trillion packaged food industry. Big Food companies, represented by firms like Matson, are urgently adapting their strategies to appeal to new consumer preferences driven by these medications. The podcast recounts visits to food innovation firms, showcasing how these companies are assessing consumer behavior and attempting to create new products that align with the flavor profiles sought by GLP-1 users.

The discussion revolves around how users of GLP-1 drugs are experiencing a shift in taste that causes them to seek out whole, natural foods over processed ones. Focus groups conducted by food companies indicate that users have become averse to ultra-processed foods, with many describing their previous favorite snacks as now unappetizing or even repugnant. This has led to an industry-wide scramble to understand and adjust marketing and product development to cater to this new demographic who are prioritizing nutritious, less processed foods.

As GLP-1 drugs reshape consumer desires, there's a debate about the responsibility of food manufacturers in this shifting landscape. With the drugs potentially reducing cravings for junk food, there is concern over whether food companies will manufacture products that inadvertently negate the drugs' effects on appetite control. The podcast raises ethical questions about the food industry's power to engineer cravings and the implications for public health.